BioCentury
ARTICLE | Product Development

How small companies can leverage big changes in rare diseases

Ovid CEO Jeremy Levin on the advantages small companies hold for tackling rare diseases

June 28, 2019 10:02 PM UTC
When you’re doing a deal as the smaller company, how important is it that you take the lead?

Small companies bring to the table a range of advantages over large ones when it comes to rare diseases, according to Ovid CEO Jeremy Levin. But he’s learned the hard way that it doesn’t help to innovate around endpoints if you can’t explain your strategy to investors.

As the company gears up for its first Phase III trial, Levin is focusing on three areas he sees as crucial for rare neurological diseases -- patient outreach, endpoints and collaborations -- as well as avoiding the missteps made in the Phase II trial...

BCIQ Company Profiles

Ovid Therapeutics Inc.